ID   KC1D_HUMAN              Reviewed;         415 AA.
AC   P48730; A2I2P2; Q96KZ6; Q9BTN5;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   27-JAN-2003, sequence version 2.
DT   12-OCT-2022, entry version 218.
DE   RecName: Full=Casein kinase I isoform delta;
DE            Short=CKI-delta;
DE            Short=CKId;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:17562708, ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20637175, ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:23636092};
DE   AltName: Full=Tau-protein kinase CSNK1D;
DE            EC=2.7.11.26 {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:17562708};
GN   Name=CSNK1D; Synonyms=HCKID;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8786104; DOI=10.1006/geno.1996.0091;
RA   Kusuda J., Hidari N., Hidari M., Hashimoto K.;
RT   "Sequence analysis of the cDNA for the human casein kinase I delta (CSNK1D)
RT   gene and its chromosomal localization.";
RL   Genomics 32:140-143(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Hematopoietic stem cell;
RX   PubMed=15070676; DOI=10.1182/blood-2003-08-2768;
RA   Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H.,
RA   Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M.,
RA   Matsui T.;
RT   "Involvement of casein kinase Iepsilon in cytokine-induced granulocytic
RT   differentiation.";
RL   Blood 103:2997-3004(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACTIVITY REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=9632646; DOI=10.1074/jbc.273.26.15980;
RA   Rivers A., Gietzen K.F., Vielhaber E., Virshup D.M.;
RT   "Regulation of casein kinase I epsilon and casein kinase I delta by an in
RT   vivo futile phosphorylation cycle.";
RL   J. Biol. Chem. 273:15980-15984(1998).
RN   [7]
RP   FUNCTION AS TP53 KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [8]
RP   INTERACTION WITH TUBULINS, AND SUBCELLULAR LOCATION.
RX   PubMed=10826492; DOI=10.1078/s0171-9335(04)70027-8;
RA   Behrend L., Stoeter M., Kurth M., Rutter G., Heukeshoven J., Deppert W.,
RA   Knippschild U.;
RT   "Interaction of casein kinase 1 delta (CK1delta) with post-Golgi
RT   structures, microtubules and the spindle apparatus.";
RL   Eur. J. Cell Biol. 79:240-251(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-38 AND THR-176.
RX   PubMed=11161704; DOI=10.1006/excr.2000.5100;
RA   Milne D.M., Looby P., Meek D.W.;
RT   "Catalytic activity of protein kinase CK1 delta (casein kinase 1delta) is
RT   essential for its normal subcellular localization.";
RL   Exp. Cell Res. 263:43-54(2001).
RN   [10]
RP   INTERACTION WITH PER1 AND PER2.
RX   PubMed=11165242; DOI=10.1016/s0014-5793(00)02434-0;
RA   Camacho F., Cilio M., Guo Y., Virshup D.M., Patel K., Khorkova O.,
RA   Styren S., Morse B., Yao Z., Keesler G.A.;
RT   "Human casein kinase Idelta phosphorylation of human circadian clock
RT   proteins period 1 and 2.";
RL   FEBS Lett. 489:159-165(2001).
RN   [11]
RP   FUNCTION AS CONNEXIN-43/GJA1 KINASE, INTERACTION WITH CONNEXIN-43/GJA1, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=12270943; DOI=10.1074/jbc.m209427200;
RA   Cooper C.D., Lampe P.D.;
RT   "Casein kinase 1 regulates connexin-43 gap junction assembly.";
RL   J. Biol. Chem. 277:44962-44968(2002).
RN   [12]
RP   INTERACTION WITH AKAP9/AKAP450, AND SUBCELLULAR LOCATION.
RX   PubMed=12270714; DOI=10.1016/s0022-2836(02)00857-4;
RA   Sillibourne J.E., Milne D.M., Takahashi M., Ono Y., Meek D.W.;
RT   "Centrosomal anchoring of the protein kinase CK1delta mediated by
RT   attachment to the large, coiled-coil scaffolding protein CG-NAP/AKAP450.";
RL   J. Mol. Biol. 322:785-797(2002).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [14]
RP   FUNCTION AS MAPT/TAU KINASE, ACTIVITY REGULATION, INTERACTION WITH
RP   MAPT/TAU, AND CATALYTIC ACTIVITY.
RX   PubMed=14761950; DOI=10.1074/jbc.m314116200;
RA   Li G., Yin H., Kuret J.;
RT   "Casein kinase 1 delta phosphorylates tau and disrupts its binding to
RT   microtubules.";
RL   J. Biol. Chem. 279:15938-15945(2004).
RN   [15]
RP   FUNCTION IN MITOTIC SPINDLE FORMATION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DEVELOPMENTAL STAGE, AND ACTIVITY REGULATION.
RX   PubMed=16027726; DOI=10.1038/sj.onc.1208941;
RA   Stoeter M., Bamberger A.-M., Aslan B., Kurth M., Speidel D., Loening T.,
RA   Frank H.-G., Kaufmann P., Loehler J., Henne-Bruns D., Deppert W.,
RA   Knippschild U.;
RT   "Inhibition of casein kinase I delta alters mitotic spindle formation and
RT   induces apoptosis in trophoblast cells.";
RL   Oncogene 24:7964-7975(2005).
RN   [16]
RP   CATALYTIC ACTIVITY, AND INTERACTION WITH DBNDD2.
RX   PubMed=16618118; DOI=10.1021/bi052354e;
RA   Yin H., Laguna K.A., Li G., Kuret J.;
RT   "Dysbindin structural homologue CK1BP is an isoform-selective binding
RT   partner of human casein kinase-1.";
RL   Biochemistry 45:5297-5308(2006).
RN   [17]
RP   FUNCTION AS PKD2 KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=17962809; DOI=10.1038/sj.emboj.7601891;
RA   von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A., Auer A.,
RA   Van Lint J., Adler G., Seufferlein T.;
RT   "Phosphorylation at Ser244 by CK1 determines nuclear localization and
RT   substrate targeting of PKD2.";
RL   EMBO J. 26:4619-4633(2007).
RN   [18]
RP   FUNCTION AS MAPT/TAU KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=17562708; DOI=10.1074/jbc.m703269200;
RA   Hanger D.P., Byers H.L., Wray S., Leung K.-Y., Saxton M.J., Seereeram A.,
RA   Reynolds C.H., Ward M.A., Anderton B.H.;
RT   "Novel phosphorylation sites in tau from Alzheimer brain support a role for
RT   casein kinase 1 in disease pathogenesis.";
RL   J. Biol. Chem. 282:23645-23654(2007).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331 AND SER-384, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=19591487; DOI=10.1021/jm9005127;
RA   Peifer C., Abadleh M., Bischof J., Hauser D., Schattel V., Hirner H.,
RA   Knippschild U., Laufer S.;
RT   "3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of
RT   p38alpha mitogen activated protein kinase and casein kinase 1delta.";
RL   J. Med. Chem. 52:7618-7630(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   FUNCTION AS TOP2A KINASE, ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=19043076; DOI=10.1093/nar/gkn934;
RA   Grozav A.G., Chikamori K., Kozuki T., Grabowski D.R., Bukowski R.M.,
RA   Willard B., Kinter M., Andersen A.H., Ganapathi R., Ganapathi M.K.;
RT   "Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at
RT   serine-1106 and modulates DNA cleavage activity.";
RL   Nucleic Acids Res. 37:382-392(2009).
RN   [25]
RP   RETRACTED PAPER.
RX   PubMed=19339517; DOI=10.1093/nar/gkp136;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J., Thomas R.S.,
RA   Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an
RT   estrogen-dependent manner and regulates ERalpha-AIB1 interactions.";
RL   Nucleic Acids Res. 37:3110-3123(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   FUNCTION AS DCK KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=20637175; DOI=10.1016/j.abb.2010.07.009;
RA   Smal C., Vertommen D., Amsailale R., Arts A., Degand H., Morsomme P.,
RA   Rider M.H., Neste E.V., Bontemps F.;
RT   "Casein kinase 1delta activates human recombinant deoxycytidine kinase by
RT   Ser-74 phosphorylation, but is not involved in the in vivo regulation of
RT   its activity.";
RL   Arch. Biochem. Biophys. 502:44-52(2010).
RN   [28]
RP   FUNCTION AS P53/TP53 KINASE, GENE FAMILY, AND CATALYTIC ACTIVITY.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [29]
RP   FUNCTION AS YAP1 KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=20048001; DOI=10.1101/gad.1843810;
RA   Zhao B., Li L., Tumaneng K., Wang C.-Y., Guan K.-L.;
RT   "A coordinated phosphorylation by Lats and CK1 regulates YAP stability
RT   through SCF(beta-TRCP).";
RL   Genes Dev. 24:72-85(2010).
RN   [30]
RP   FUNCTION AS HIF1A KINASE, AND CATALYTIC ACTIVITY.
RX   PubMed=20699359; DOI=10.1242/jcs.068122;
RA   Kalousi A., Mylonis I., Politou A.S., Chachami G., Paraskeva E., Simos G.;
RT   "Casein kinase 1 regulates human hypoxia-inducible factor HIF-1.";
RL   J. Cell Sci. 123:2976-2986(2010).
RN   [31]
RP   FUNCTION IN CIRCADIAN RHYTHMS, AND ACTIVITY REGULATION.
RX   PubMed=20696890; DOI=10.1073/pnas.1005101107;
RA   Meng Q.-J., Maywood E.S., Bechtold D.A., Lu W.-Q., Li J., Gibbs J.E.,
RA   Dupre S.M., Chesham J.E., Rajamohan F., Knafels J., Sneed B.,
RA   Zawadzke L.E., Ohren J.F., Walton K.M., Wager T.T., Hastings M.H.,
RA   Loudon A.S.I.;
RT   "Entrainment of disrupted circadian behavior through inhibition of casein
RT   kinase 1 (CK1) enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15240-15245(2010).
RN   [32]
RP   FUNCTION IN CIRCADIAN RHYTHMS, AND ACTIVITY REGULATION.
RX   PubMed=20407760; DOI=10.1007/s00213-010-1860-5;
RA   Sprouse J., Reynolds L., Kleiman R., Tate B., Swanson T.A., Pickard G.E.;
RT   "Chronic treatment with a selective inhibitor of casein kinase I
RT   delta/epsilon yields cumulative phase delays in circadian rhythms.";
RL   Psychopharmacology 210:569-576(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   FUNCTION AS EIF6 KINASE, ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=21084295; DOI=10.1074/jbc.m110.188565;
RA   Biswas A., Mukherjee S., Das S., Shields D., Chow C.W., Maitra U.;
RT   "Opposing action of casein kinase 1 and calcineurin in nucleo-cytoplasmic
RT   shuttling of mammalian translation initiation factor eIF6.";
RL   J. Biol. Chem. 286:3129-3138(2011).
RN   [36]
RP   FUNCTION AS DVL2 AND DVL3 KINASE, ACTIVITY REGULATION, SUBCELLULAR
RP   LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=21422228; DOI=10.1083/jcb.201011111;
RA   Greer Y.E., Rubin J.S.;
RT   "Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a-
RT   dependent neurite outgrowth.";
RL   J. Cell Biol. 192:993-1004(2011).
RN   [37]
RP   ACTIVITY REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=21258417; DOI=10.1038/onc.2010.627;
RA   Cheong J.K., Nguyen T.H., Wang H., Tan P., Voorhoeve P.M., Lee S.H.,
RA   Virshup D.M.;
RT   "IC261 induces cell cycle arrest and apoptosis of human cancer cells via
RT   CK1delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic
RT   spindle formation.";
RL   Oncogene 30:2558-2569(2011).
RN   [38]
RP   REVIEW ON CIRCADIAN RHYTHMS, AND GENE FAMILY.
RX   PubMed=21145983; DOI=10.1016/j.biocel.2010.12.004;
RA   Cheong J.K., Virshup D.M.;
RT   "Casein kinase 1: Complexity in the family.";
RL   Int. J. Biochem. Cell Biol. 43:465-469(2011).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328; SER-331; SER-382;
RP   SER-384 AND SER-407, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   INTERACTION WITH DDX3X.
RX   PubMed=29222110; DOI=10.1242/jcs.207316;
RA   Dolde C., Bischof J., Grueter S., Montada A., Halekotte J., Peifer C.,
RA   Kalbacher H., Baumann U., Knippschild U., Suter B.;
RT   "A CK1 FRET biosensor reveals that DDX3X is an essential activator of
RT   CK1epsilon.";
RL   J. Cell Sci. 131:0-0(2018).
RN   [42]
RP   RETRACTION NOTICE OF PUBMED:19339517.
RX   PubMed=34718754; DOI=10.1093/nar/gkab845;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J., Thomas R.S.,
RA   Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "Retraction of 'CK1delta modulates the transcriptional activity of ERalpha
RT   via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1
RT   interactions'.";
RL   Nucleic Acids Res. 49:12006-12006(2021).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=9761932; DOI=10.1107/s0907444997011724;
RA   Longenecker K.L., Roach P.J., Hurley T.D.;
RT   "Crystallographic studies of casein kinase I delta toward a structural
RT   understanding of auto-inhibition.";
RL   Acta Crystallogr. D 54:473-475(1998).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 1-294 IN COMPLEX WITH INHIBITOR,
RP   AND SUBUNIT.
RX   PubMed=22168824; DOI=10.1021/jm201387s;
RA   Long A., Zhao H., Huang X.;
RT   "Structural basis for the interaction between casein kinase 1 delta and a
RT   potent and selective inhibitor.";
RL   J. Med. Chem. 55:956-960(2012).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 1-294 IN COMPLEX WITH INHIBITOR,
RP   AND SUBUNIT.
RX   PubMed=23106386; DOI=10.1021/jm301336n;
RA   Long A.M., Zhao H., Huang X.;
RT   "Structural basis for the potent and selective inhibition of casein kinase
RT   1 epsilon.";
RL   J. Med. Chem. 55:10307-10311(2012).
RN   [46]
RP   VARIANT FASPS2 ALA-44.
RX   PubMed=15800623; DOI=10.1038/nature03453;
RA   Xu Y., Padiath Q.S., Shapiro R.E., Jones C.R., Wu S.C., Saigoh N.,
RA   Saigoh K., Ptacek L.J., Fu Y.H.;
RT   "Functional consequences of a CKIdelta mutation causing familial advanced
RT   sleep phase syndrome.";
RL   Nature 434:640-644(2005).
RN   [47]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-97.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [48]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-97 AND ALA-401.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [49]
RP   VARIANTS FASPS2 ALA-44 AND ARG-46, CHARACTERIZATION OF VARIANTS FASPS2
RP   ALA-44 AND ARG-46, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=23636092; DOI=10.1126/scitranslmed.3005784;
RA   Brennan K.C., Bates E.A., Shapiro R.E., Zyuzin J., Hallows W.C., Huang Y.,
RA   Lee H.Y., Jones C.R., Fu Y.H., Charles A.C., Ptacek L.J.;
RT   "Casein kinase idelta mutations in familial migraine and advanced phase.";
RL   Sci. Transl. Med. 5:183ra56-183ra56(2013).
CC   -!- FUNCTION: Essential serine/threonine-protein kinase that regulates
CC       diverse cellular growth and survival processes including Wnt signaling,
CC       DNA repair and circadian rhythms. It can phosphorylate a large number
CC       of proteins. Casein kinases are operationally defined by their
CC       preferential utilization of acidic proteins such as caseins as
CC       substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU,
CC       TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1,
CC       PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In
CC       balance with PP1, determines the circadian period length through the
CC       regulation of the speed and rhythmicity of PER1 and PER2
CC       phosphorylation. Controls PER1 and PER2 nuclear transport and
CC       degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3
CC       ubiquitin ligase-mediated ubiquitination and subsequent degradation.
CC       DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation
CC       of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation.
CC       Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that
CC       controls neurite outgrowth. Phosphorylates NEDD9/HEF1 (By similarity).
CC       EIF6 phosphorylation promotes its nuclear export. Triggers down-
CC       regulation of dopamine receptors in the forebrain. Activates DCK in
CC       vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable
CC       complex formation. May regulate the formation of the mitotic spindle
CC       apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap
CC       junction assembly by phosphorylation. Probably involved in lymphocyte
CC       physiology. Regulates fast synaptic transmission mediated by glutamate.
CC       {ECO:0000250|UniProtKB:Q9DC28, ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:12270943, ECO:0000269|PubMed:14761950,
CC       ECO:0000269|PubMed:16027726, ECO:0000269|PubMed:17562708,
CC       ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:19043076,
CC       ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20048001,
CC       ECO:0000269|PubMed:20407760, ECO:0000269|PubMed:20637175,
CC       ECO:0000269|PubMed:20696890, ECO:0000269|PubMed:20699359,
CC       ECO:0000269|PubMed:21084295, ECO:0000269|PubMed:21422228,
CC       ECO:0000269|PubMed:23636092}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:12270943, ECO:0000269|PubMed:14761950,
CC         ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:17562708,
CC         ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:19043076,
CC         ECO:0000269|PubMed:19591487, ECO:0000269|PubMed:20041275,
CC         ECO:0000269|PubMed:20048001, ECO:0000269|PubMed:20637175,
CC         ECO:0000269|PubMed:20699359, ECO:0000269|PubMed:21084295,
CC         ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:23636092};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000305|PubMed:20637175};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10606744,
CC         ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:17562708,
CC         ECO:0000269|PubMed:19591487, ECO:0000269|PubMed:20041275,
CC         ECO:0000269|PubMed:20637175, ECO:0000269|PubMed:21422228,
CC         ECO:0000269|PubMed:23636092};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000305|PubMed:20637175};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC         Evidence={ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16618118,
CC         ECO:0000269|PubMed:17562708};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12802;
CC         Evidence={ECO:0000305|PubMed:14761950};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26; Evidence={ECO:0000269|PubMed:14761950,
CC         ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:17562708};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53905;
CC         Evidence={ECO:0000305|PubMed:14761950};
CC   -!- ACTIVITY REGULATION: Exhibits substrate-dependent heparin activation.
CC       Drug-mediated inhibition leads to a delay of the oscillations with the
CC       magnitude of this effect dependent upon the timing of drug
CC       administration. Inhibited by phosphorylation. Repressed by 3-[(2,4,6-
CC       trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261), N-(2-aminoethyl)-
CC       5-chloroisoquinoline-8-sulfonamide (CKI-7), 4-[4-(2,3-dihydro-
CC       benzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
CC       (D4476), 3,4-diaryl-isoxazoles and -imidazoles, and 4-(3-cyclohexyl-5-
CC       (4-fluoro-phenyl)-3H-imidazol-4-yl) pyrimidin-2-ylamine (PF670462,
CC       PF670). {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16027726,
CC       ECO:0000269|PubMed:19043076, ECO:0000269|PubMed:19591487,
CC       ECO:0000269|PubMed:20407760, ECO:0000269|PubMed:20696890,
CC       ECO:0000269|PubMed:21084295, ECO:0000269|PubMed:21258417,
CC       ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:9632646}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=36.5 uM for alpha-casein {ECO:0000269|PubMed:23636092};
CC         KM=635.8 uM for PER2 peptide {ECO:0000269|PubMed:23636092};
CC         KM=180.6 uM for ATP {ECO:0000269|PubMed:23636092};
CC         Note=Maximal velocity nearly identical for the reactions with
CC         alpha-casein and PER2 peptide.;
CC   -!- SUBUNIT: Monomer (PubMed:22168824, PubMed:23106386). Component of the
CC       circadian core oscillator, which includes the CRY proteins, CLOCK, or
CC       NPAS2, ARTNL/BMAL1 or ARTNL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and
CC       the PER proteins (By similarity). Interacts with DNMT1 and MAP1A (By
CC       similarity). Interacts directly with PER1 and PER2 which may lead to
CC       their degradation (PubMed:11165242). Interacts with MAPT/TAU
CC       (PubMed:14761950). Interacts with SNAPIN (By similarity). Interacts
CC       with DBNDD2 (PubMed:16618118). Interacts with AKAP9/AKAP450; this
CC       interaction promotes centrosomal subcellular location
CC       (PubMed:12270714). Binds to tubulins in mitotic cells upon DNA damage
CC       (PubMed:10826492). Interacts with GJA1 (PubMed:12270943). Interacts
CC       with DDX3X; this interaction enhances CSNK1D kinase activity in vitro,
CC       but it is unclear whether this interaction is physiologically relevant
CC       (PubMed:29222110). {ECO:0000250|UniProtKB:Q06486,
CC       ECO:0000250|UniProtKB:Q9DC28, ECO:0000269|PubMed:10826492,
CC       ECO:0000269|PubMed:11165242, ECO:0000269|PubMed:12270714,
CC       ECO:0000269|PubMed:12270943, ECO:0000269|PubMed:14761950,
CC       ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:22168824,
CC       ECO:0000269|PubMed:23106386, ECO:0000269|PubMed:29222110}.
CC   -!- INTERACTION:
CC       P48730; P05067: APP; NbExp=3; IntAct=EBI-751621, EBI-77613;
CC       P48730; Q49A88-3: CCDC14; NbExp=3; IntAct=EBI-751621, EBI-12105646;
CC       P48730; Q6PGQ1: DRICH1; NbExp=3; IntAct=EBI-751621, EBI-10253641;
CC       P48730; Q92997: DVL3; NbExp=4; IntAct=EBI-751621, EBI-739789;
CC       P48730; O60447: EVI5; NbExp=3; IntAct=EBI-751621, EBI-852291;
CC       P48730; Q9H2S9: IKZF4; NbExp=3; IntAct=EBI-751621, EBI-1640423;
CC       P48730; Q96LR2: LURAP1; NbExp=4; IntAct=EBI-751621, EBI-741355;
CC       P48730; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-751621, EBI-741037;
CC       P48730; Q00987: MDM2; NbExp=6; IntAct=EBI-751621, EBI-389668;
CC       P48730; Q9P286: PAK5; NbExp=3; IntAct=EBI-751621, EBI-741896;
CC       P48730; O15055: PER2; NbExp=4; IntAct=EBI-751621, EBI-1054296;
CC       P48730; O75382: TRIM3; NbExp=3; IntAct=EBI-751621, EBI-2129889;
CC       P48730; Q9C026: TRIM9; NbExp=3; IntAct=EBI-751621, EBI-720828;
CC       P48730; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-751621, EBI-742740;
CC       P48730; Q5T7W0: ZNF618; NbExp=3; IntAct=EBI-751621, EBI-6255994;
CC       P48730; Q60838: Dvl2; Xeno; NbExp=2; IntAct=EBI-751621, EBI-641940;
CC       P48730-2; P05067: APP; NbExp=3; IntAct=EBI-9087876, EBI-77613;
CC       P48730-2; Q92624: APPBP2; NbExp=3; IntAct=EBI-9087876, EBI-743771;
CC       P48730-2; Q96GW7: BCAN; NbExp=3; IntAct=EBI-9087876, EBI-2690445;
CC       P48730-2; Q8IU99: CALHM1; NbExp=3; IntAct=EBI-9087876, EBI-1790341;
CC       P48730-2; Q03135: CAV1; NbExp=3; IntAct=EBI-9087876, EBI-603614;
CC       P48730-2; P45973: CBX5; NbExp=3; IntAct=EBI-9087876, EBI-78219;
CC       P48730-2; P06850: CRH; NbExp=3; IntAct=EBI-9087876, EBI-3870390;
CC       P48730-2; Q01658: DR1; NbExp=3; IntAct=EBI-9087876, EBI-750300;
CC       P48730-2; Q9BS26: ERP44; NbExp=3; IntAct=EBI-9087876, EBI-541644;
CC       P48730-2; P35637: FUS; NbExp=3; IntAct=EBI-9087876, EBI-400434;
CC       P48730-2; P17302: GJA1; NbExp=3; IntAct=EBI-9087876, EBI-1103439;
CC       P48730-2; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-9087876, EBI-739467;
CC       P48730-2; P25098: GRK2; NbExp=3; IntAct=EBI-9087876, EBI-3904795;
CC       P48730-2; Q00403: GTF2B; NbExp=3; IntAct=EBI-9087876, EBI-389564;
CC       P48730-2; Q9Y5Q9: GTF3C3; NbExp=3; IntAct=EBI-9087876, EBI-1054873;
CC       P48730-2; P42858: HTT; NbExp=15; IntAct=EBI-9087876, EBI-466029;
CC       P48730-2; Q14114-3: LRP8; NbExp=3; IntAct=EBI-9087876, EBI-25832196;
CC       P48730-2; Q5S007: LRRK2; NbExp=3; IntAct=EBI-9087876, EBI-5323863;
CC       P48730-2; Q16539: MAPK14; NbExp=3; IntAct=EBI-9087876, EBI-73946;
CC       P48730-2; Q96L34: MARK4; NbExp=3; IntAct=EBI-9087876, EBI-302319;
CC       P48730-2; P35240-4: NF2; NbExp=3; IntAct=EBI-9087876, EBI-1014514;
CC       P48730-2; Q6ZW49: PAXIP1; NbExp=3; IntAct=EBI-9087876, EBI-743225;
CC       P48730-2; O14494: PLPP1; NbExp=3; IntAct=EBI-9087876, EBI-2865290;
CC       P48730-2; D3DTS7: PMP22; NbExp=3; IntAct=EBI-9087876, EBI-25882629;
CC       P48730-2; P17612: PRKACA; NbExp=3; IntAct=EBI-9087876, EBI-476586;
CC       P48730-2; P07602: PSAP; NbExp=3; IntAct=EBI-9087876, EBI-716699;
CC       P48730-2; P54725: RAD23A; NbExp=3; IntAct=EBI-9087876, EBI-746453;
CC       P48730-2; P04271: S100B; NbExp=3; IntAct=EBI-9087876, EBI-458391;
CC       P48730-2; Q8WTV0: SCARB1; NbExp=3; IntAct=EBI-9087876, EBI-78657;
CC       P48730-2; P50454: SERPINH1; NbExp=3; IntAct=EBI-9087876, EBI-350723;
CC       P48730-2; Q8IUQ4-2: SIAH1; NbExp=3; IntAct=EBI-9087876, EBI-11522811;
CC       P48730-2; P84022: SMAD3; NbExp=3; IntAct=EBI-9087876, EBI-347161;
CC       P48730-2; P37840: SNCA; NbExp=3; IntAct=EBI-9087876, EBI-985879;
CC       P48730-2; P00441: SOD1; NbExp=3; IntAct=EBI-9087876, EBI-990792;
CC       P48730-2; Q6NUL7: SPTLC1; NbExp=3; IntAct=EBI-9087876, EBI-25912847;
CC       P48730-2; Q13148: TARDBP; NbExp=6; IntAct=EBI-9087876, EBI-372899;
CC       P48730-2; P37173: TGFBR2; NbExp=3; IntAct=EBI-9087876, EBI-296151;
CC       P48730-2; Q9NRS4: TMPRSS4; NbExp=3; IntAct=EBI-9087876, EBI-10313040;
CC       P48730-2; Q9BVJ6: UTP14A; NbExp=3; IntAct=EBI-9087876, EBI-473284;
CC       P48730-2; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-9087876, EBI-11141397;
CC       P48730-2; Q8IUH5: ZDHHC17; NbExp=3; IntAct=EBI-9087876, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:14654843}. Cytoplasm, perinuclear region. Cell
CC       membrane. Cytoplasm, cytoskeleton, spindle. Golgi apparatus.
CC       Note=Localized at mitotic spindle microtubules, and at the centrosomes
CC       and interphase in interphase cells. Recruited to the spindle apparatus
CC       and the centrosomes in response to DNA-damage. Correct subcellular
CC       localization requires kinase activity.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48730-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48730-2; Sequence=VSP_010253;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, including brain,
CC       heart, lung, liver, pancreas, kidney, placenta and skeletal muscle.
CC       However, kinase activity is not uniform, with highest kinase activity
CC       in splenocytes. In blood, highly expressed in hemopoietic cells and
CC       mature granulocytes. Also found in monocytes and lymphocytes.
CC       {ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:16027726}.
CC   -!- DEVELOPMENTAL STAGE: Highly present in extravillous trophoblast cells,
CC       which are present at the placenta implantation site and invade the
CC       decidua and decidual vessels. {ECO:0000269|PubMed:16027726}.
CC   -!- PTM: Autophosphorylated on serine and threonine residues; this
CC       autophosphorylation represses activity. Reactivated by phosphatase-
CC       mediated dephosphorylation. May be dephosphorylated by PP1.
CC   -!- DISEASE: Advanced sleep phase syndrome, familial, 2 (FASPS2)
CC       [MIM:615224]: A disorder characterized by very early sleep onset and
CC       offset. Individuals are 'morning larks' with a 4 hours advance of the
CC       sleep, temperature and melatonin rhythms. {ECO:0000269|PubMed:15800623,
CC       ECO:0000269|PubMed:23636092}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: May be involved in Alzheimer disease by phosphorylating
CC       MAPT/TAU. {ECO:0000305|PubMed:17562708}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. Casein kinase I subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was shown to phosphorylate and activate DCK in vitro but
CC       probably not in vivo. {ECO:0000305|PubMed:20637175}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U29171; AAC50807.1; -; mRNA.
DR   EMBL; U31285; AAC50808.1; -; mRNA.
DR   EMBL; AB091044; BAC10903.1; -; mRNA.
DR   EMBL; AK291758; BAF84447.1; -; mRNA.
DR   EMBL; EF015900; ABM64211.1; -; Genomic_DNA.
DR   EMBL; BC003558; AAH03558.1; -; mRNA.
DR   EMBL; BC015775; AAH15775.1; -; mRNA.
DR   CCDS; CCDS11805.1; -. [P48730-1]
DR   CCDS; CCDS11806.1; -. [P48730-2]
DR   PIR; G01876; G01876.
DR   RefSeq; NP_001884.2; NM_001893.4. [P48730-1]
DR   RefSeq; NP_620693.1; NM_139062.2. [P48730-2]
DR   PDB; 3UYS; X-ray; 2.30 A; A/B/C/D=1-294.
DR   PDB; 3UYT; X-ray; 2.00 A; A/B/C/D=1-294.
DR   PDB; 3UZP; X-ray; 1.94 A; A/B=1-294.
DR   PDB; 4HGT; X-ray; 1.80 A; A/B=1-294.
DR   PDB; 4HNF; X-ray; 2.07 A; A/B=1-294.
DR   PDB; 4KB8; X-ray; 1.95 A; A/B/C/D=3-317.
DR   PDB; 4KBA; X-ray; 1.98 A; A/B/C/D=3-317.
DR   PDB; 4KBC; X-ray; 1.98 A; A/B=1-317.
DR   PDB; 4KBK; X-ray; 2.10 A; A/B/C/D=3-317.
DR   PDB; 4TN6; X-ray; 2.41 A; A/B=1-301.
DR   PDB; 4TW9; X-ray; 2.40 A; A/B=1-295.
DR   PDB; 4TWC; X-ray; 1.70 A; A/B=1-295.
DR   PDB; 5IH4; X-ray; 1.90 A; A=1-294.
DR   PDB; 5IH5; X-ray; 2.25 A; A=1-294.
DR   PDB; 5IH6; X-ray; 2.30 A; A=1-294.
DR   PDB; 5MQV; X-ray; 2.15 A; A/B/C/D/E/F=1-294.
DR   PDB; 5OKT; X-ray; 2.13 A; A/B/C/D=1-294.
DR   PDB; 5W4W; X-ray; 1.99 A; A/B/C/D=3-317.
DR   PDB; 6F1W; X-ray; 1.86 A; A/B=1-294.
DR   PDB; 6F26; X-ray; 1.83 A; A/B=1-294.
DR   PDB; 6GZM; X-ray; 1.59 A; A/B=1-295.
DR   PDB; 6HMP; X-ray; 2.04 A; A/B=1-294.
DR   PDB; 6HMR; X-ray; 1.78 A; A/B=1-294.
DR   PDB; 6PXN; X-ray; 1.55 A; A/B=1-415.
DR   PDB; 6PXO; X-ray; 2.00 A; A/B=1-294.
DR   PDB; 6PXP; X-ray; 2.35 A; A/B=1-294.
DR   PDB; 6RCG; X-ray; 1.40 A; A=1-294.
DR   PDB; 6RCH; X-ray; 1.45 A; A/B=1-294.
DR   PDB; 6RU6; X-ray; 2.05 A; A/B=1-294.
DR   PDB; 6RU7; X-ray; 2.08 A; A/B=1-294.
DR   PDB; 6RU8; X-ray; 1.92 A; A/B/C/D=1-294.
DR   PDB; 7P7F; X-ray; 1.96 A; A/B/C/D=1-294.
DR   PDB; 7P7G; X-ray; 1.70 A; A/B=1-294.
DR   PDB; 7P7H; X-ray; 2.40 A; A/B=1-294.
DR   PDBsum; 3UYS; -.
DR   PDBsum; 3UYT; -.
DR   PDBsum; 3UZP; -.
DR   PDBsum; 4HGT; -.
DR   PDBsum; 4HNF; -.
DR   PDBsum; 4KB8; -.
DR   PDBsum; 4KBA; -.
DR   PDBsum; 4KBC; -.
DR   PDBsum; 4KBK; -.
DR   PDBsum; 4TN6; -.
DR   PDBsum; 4TW9; -.
DR   PDBsum; 4TWC; -.
DR   PDBsum; 5IH4; -.
DR   PDBsum; 5IH5; -.
DR   PDBsum; 5IH6; -.
DR   PDBsum; 5MQV; -.
DR   PDBsum; 5OKT; -.
DR   PDBsum; 5W4W; -.
DR   PDBsum; 6F1W; -.
DR   PDBsum; 6F26; -.
DR   PDBsum; 6GZM; -.
DR   PDBsum; 6HMP; -.
DR   PDBsum; 6HMR; -.
DR   PDBsum; 6PXN; -.
DR   PDBsum; 6PXO; -.
DR   PDBsum; 6PXP; -.
DR   PDBsum; 6RCG; -.
DR   PDBsum; 6RCH; -.
DR   PDBsum; 6RU6; -.
DR   PDBsum; 6RU7; -.
DR   PDBsum; 6RU8; -.
DR   PDBsum; 7P7F; -.
DR   PDBsum; 7P7G; -.
DR   PDBsum; 7P7H; -.
DR   AlphaFoldDB; P48730; -.
DR   SMR; P48730; -.
DR   BioGRID; 107837; 217.
DR   DIP; DIP-39735N; -.
DR   IntAct; P48730; 161.
DR   MINT; P48730; -.
DR   STRING; 9606.ENSP00000324464; -.
DR   BindingDB; P48730; -.
DR   ChEMBL; CHEMBL2828; -.
DR   DrugCentral; P48730; -.
DR   GuidetoPHARMACOLOGY; 1997; -.
DR   iPTMnet; P48730; -.
DR   PhosphoSitePlus; P48730; -.
DR   BioMuta; CSNK1D; -.
DR   DMDM; 27923980; -.
DR   EPD; P48730; -.
DR   jPOST; P48730; -.
DR   MassIVE; P48730; -.
DR   MaxQB; P48730; -.
DR   PaxDb; P48730; -.
DR   PeptideAtlas; P48730; -.
DR   PRIDE; P48730; -.
DR   ProteomicsDB; 55930; -. [P48730-1]
DR   ProteomicsDB; 55931; -. [P48730-2]
DR   TopDownProteomics; P48730-1; -. [P48730-1]
DR   Antibodypedia; 4210; 375 antibodies from 39 providers.
DR   DNASU; 1453; -.
DR   Ensembl; ENST00000314028.11; ENSP00000324464.6; ENSG00000141551.15. [P48730-1]
DR   Ensembl; ENST00000392334.6; ENSP00000376146.2; ENSG00000141551.15. [P48730-2]
DR   GeneID; 1453; -.
DR   KEGG; hsa:1453; -.
DR   MANE-Select; ENST00000314028.11; ENSP00000324464.6; NM_001893.6; NP_001884.2.
DR   UCSC; uc002kei.4; human. [P48730-1]
DR   CTD; 1453; -.
DR   DisGeNET; 1453; -.
DR   GeneCards; CSNK1D; -.
DR   HGNC; HGNC:2452; CSNK1D.
DR   HPA; ENSG00000141551; Low tissue specificity.
DR   MalaCards; CSNK1D; -.
DR   MIM; 600864; gene.
DR   MIM; 615224; phenotype.
DR   neXtProt; NX_P48730; -.
DR   OpenTargets; ENSG00000141551; -.
DR   Orphanet; 164736; Familial advanced sleep-phase syndrome.
DR   PharmGKB; PA26952; -.
DR   VEuPathDB; HostDB:ENSG00000141551; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   GeneTree; ENSGT00940000153536; -.
DR   HOGENOM; CLU_019279_2_2_1; -.
DR   InParanoid; P48730; -.
DR   OMA; IFDWTFL; -.
DR   OrthoDB; 1097975at2759; -.
DR   PhylomeDB; P48730; -.
DR   TreeFam; TF300544; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.11.26; 2681.
DR   PathwayCommons; P48730; -.
DR   Reactome; R-HSA-204005; COPII-mediated vesicle transport.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SABIO-RK; P48730; -.
DR   SignaLink; P48730; -.
DR   SIGNOR; P48730; -.
DR   BioGRID-ORCS; 1453; 24 hits in 1120 CRISPR screens.
DR   ChiTaRS; CSNK1D; human.
DR   GeneWiki; CSNK1D; -.
DR   GenomeRNAi; 1453; -.
DR   Pharos; P48730; Tchem.
DR   PRO; PR:P48730; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P48730; protein.
DR   Bgee; ENSG00000141551; Expressed in left testis and 203 other tissues.
DR   ExpressionAtlas; P48730; baseline and differential.
DR   Genevisible; P48730; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0007030; P:Golgi organization; IMP:SYSCILIA_CCNET.
DR   GO; GO:0007020; P:microtubule nucleation; IMP:SYSCILIA_CCNET.
DR   GO; GO:1905515; P:non-motile cilium assembly; IMP:SYSCILIA_CCNET.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:1905426; P:positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation; IC:ParkinsonsUK-UCL.
DR   GO; GO:0071539; P:protein localization to centrosome; IMP:SYSCILIA_CCNET.
DR   GO; GO:0061512; P:protein localization to cilium; IMP:SYSCILIA_CCNET.
DR   GO; GO:0034067; P:protein localization to Golgi apparatus; IMP:SYSCILIA_CCNET.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0051225; P:spindle assembly; IDA:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Cell membrane; Cytoplasm; Cytoskeleton; Disease variant; Golgi apparatus;
KW   Kinase; Membrane; Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN           1..415
FT                   /note="Casein kinase I isoform delta"
FT                   /id="PRO_0000192833"
FT   DOMAIN          9..277
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          278..364
FT                   /note="Centrosomal localization signal (CLS)"
FT   REGION          301..415
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          317..342
FT                   /note="Autoinhibitory"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        301..320
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        342..359
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        380..415
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        128
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         15..23
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         38
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         328
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         370
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06486"
FT   MOD_RES         375
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9DC28"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         400..415
FT                   /note="IPGRVASSGLQSVVHR -> NSIPFEHHGK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010253"
FT   VARIANT         44
FT                   /note="T -> A (in FASPS2; strongly reduces kinase activity;
FT                   dbSNP:rs104894561)"
FT                   /evidence="ECO:0000269|PubMed:15800623,
FT                   ECO:0000269|PubMed:23636092"
FT                   /id="VAR_029075"
FT   VARIANT         46
FT                   /note="H -> R (in FASPS2; strongly reduces kinase activity;
FT                   dbSNP:rs397514693)"
FT                   /evidence="ECO:0000269|PubMed:23636092"
FT                   /id="VAR_069801"
FT   VARIANT         97
FT                   /note="S -> C (in breast cancer samples; infiltrating
FT                   ductal carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_036451"
FT   VARIANT         401
FT                   /note="P -> A (in dbSNP:rs56124628)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042081"
FT   MUTAGEN         38
FT                   /note="K->M: Impaired kinase activity and abnormal
FT                   subcellular localization with exclusive accumulation to the
FT                   nucleus."
FT                   /evidence="ECO:0000269|PubMed:11161704"
FT   MUTAGEN         176
FT                   /note="T->I: Impaired kinase activity and abnormal
FT                   subcellular localization with exclusive accumulation to the
FT                   nucleus."
FT                   /evidence="ECO:0000269|PubMed:11161704"
FT   CONFLICT        330
FT                   /note="A -> D (in Ref. 1; AAC50807)"
FT                   /evidence="ECO:0000305"
FT   STRAND          3..5
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   TURN            6..8
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          9..18
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          21..28
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   TURN            29..32
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          33..41
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          44..46
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           49..59
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          77..83
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           89..95
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   TURN            96..98
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           102..121
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           131..133
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          134..136
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   STRAND          154..157
FT                   /evidence="ECO:0007829|PDB:4TWC"
FT   TURN            159..161
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           192..208
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   TURN            212..215
FT                   /evidence="ECO:0007829|PDB:6RCH"
FT   STRAND          217..219
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           221..233
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           237..240
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   TURN            241..243
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           247..257
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           266..279
FT                   /evidence="ECO:0007829|PDB:6RCG"
FT   HELIX           280..283
FT                   /evidence="ECO:0007829|PDB:6F1W"
FT   HELIX           289..292
FT                   /evidence="ECO:0007829|PDB:6RCG"
SQ   SEQUENCE   415 AA;  47330 MW;  B97F1717A52466D2 CRC64;
     MELRVGNRYR LGRKIGSGSF GDIYLGTDIA AGEEVAIKLE CVKTKHPQLH IESKIYKMMQ
     GGVGIPTIRW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH
     SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA
     SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL
     CKGYPSEFAT YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGASRA
     ADDAERERRD REERLRHSRN PATRGLPSTA SGRLRGTQEV APPTPLTPTS HTANTSPRPV
     SGMERERKVS MRLHRGAPVN ISSSDLTGRQ DTSRMSTSQI PGRVASSGLQ SVVHR
//
